表紙
市場調查報告書

全球水痘活病毒疫苗市場:各產品、用途、供應商 - 機會分析及產業預測(2018年∼2026年)

Varicella Live Vaccine Market by Product, Application, and Provider : Global Opportunity Analysis and Industry Forecast, 2018-2026

出版商 Allied Market Research 商品編碼 917235
出版日期 內容資訊 英文 178 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球水痘活病毒疫苗市場:各產品、用途、供應商 - 機會分析及產業預測(2018年∼2026年) Varicella Live Vaccine Market by Product, Application, and Provider : Global Opportunity Analysis and Industry Forecast, 2018-2026
出版日期: 2019年10月01日內容資訊: 英文 178 Pages
簡介

全球水痘活病毒疫苗市場在2018年估算為27記憶1,400萬美金。該市場在2019年∼2025年間,預測將以5.7%的年複合成長率成長,2026年達到42記憶2,200萬美元。

本報告提供全球水痘活病毒疫苗市場的相關調查,市場機會和影響,成長及阻礙因素,各產品、用途、供應商、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 報告的說明
  • 利害關係者的主要優點
  • 主要市場區隔
    • 本報告調查的主要企業的清單
  • 調查方法
    • 二次調查
    • 一次調查
    • 分析師的工具和模式

第2章 摘要整理

  • 主要調查結果
  • Cxo的見解

第3章 市場概要

  • 市場定義、範圍
  • 主要調查結果
    • 主要的投資品牌
  • 波特的五力分析
    • 買主談判力
    • 供應商談判力
    • 新生的話
    • 替代品的威脅
    • 產業內的競爭
  • 主要企業的地位
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第4章 市場分析:各產品

  • 概要
    • 市場規模、預測
  • 1價值
    • 主要的市場趨勢及成長機會
    • 市場規模、預測:各地區
    • 市場分析:各國
  • 多效價

第5章 市場分析:各用途

  • 概要
    • 市場規模、預測
  • 水痘
    • 市場規模、預測:各地區
    • 市場分析:各國
  • 帶狀皰疹
  • 腮腺炎,麻疹,德國麻疹,水痘(MMRV)

第6章 市場分析:各供應商

  • 概要
    • 市場規模、預測
  • 公共
    • 市場規模、預測:各地區
    • 市場分析:各國
  • 民間

第7章 市場分析:各地區

  • 概要
    • 市場規模、預測
  • 北美
    • 主要市場趨勢、機會
    • 市場分析:各國
    • 各產品
    • 各用途
    • 各供應商
  • 歐洲
  • 亞太地區
  • 南美、中東、非洲

第8章 企業簡介

  • Bio-Med Pvt. Limited
  • Changchun Bcht Biotechnology Co. Ltd.
  • Emcure Pharmaceuticals Limited (Zuventus Healthcare Ltd.)
  • Glaxosmithkline Plc
  • Green Cross Holdings (Gc Pharma)
  • Merck & Co. Inc.
  • 株式會社三菱化學控股 (田邊三菱製藥株式會社)
  • Novo Medi Sciences Pvt. Ltd.
  • Sanofi
  • 武田藥品工業株式會社
目錄
Product Code: LI_183969

Title:
Varicella Live Vaccine Market by Product (Monovalent Varicella Vaccine and Combination Varicella Vaccine), Application (Chickenpox Immunization, Herpes Zoster Immunization, and MMRV Immunization), and Provider (Public Provider, and Private Provider): Global Opportunity Analysis and Industry Forecast, 2018-2026.

The global varicella live vaccine market was valued at $2,714 million in 2018, and is expected to reach $4,222 million by 2026, registering a CAGR of 5.7% from 2019 to 2026.

Varicella live vaccines contain an attenuated form of the varicella zoster virus. These vaccines help build immunity against varicella zoster virus as the infection can cause serious diseases such as chicken pox and herpes zoster. Immunization against these diseases is necessary as chicken pox can lead to serious complications such as bacterial infections of the skin and soft tissues in children. Moreover, herpes zoster is another painful condition that is caused by the reactivation of the varicella zoster virus after primary infection. Therefore, immunization with varicella live vaccine serves as an effective method for prevention of these diseases. These vaccines are mainly of two types such as monovalent and combination. The monovalent vaccines contain a single strain of a single antigen such as varicella live vaccines, contain weakened strain of varicella zoster virus. However, the combination varicella vaccines contain multiple strains of infectious agents.

The factors that boost the growth of the varicella live vaccine market include surge in immunization programs across the globe. Moreover, rise in awareness related to the use of varicella live vaccines and surge in adoption of varicella vaccination worldwide also fuel the growth of the varicella live vaccine market. However, high monetary inputs associated with the production of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

The global varicella live vaccine market is segmented based on product, application, provider, and region. On the basis of product, the market is bifurcated into monovalent varicella vaccine and combination varicella vaccine. By application, it is divided into chicken pox immunization, herpes zoster immunization and measles, mumps, rubella, and varicella (MMRV) immunization. On the basis of provider, it is segmented into public provider and private provider. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis along with the current global varicella live vaccine market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Product

  • Monovalent Varicella Vaccine
  • Combination Varicella Vaccine

By Application

  • Chickenpox immunization
  • Herpes Zoster Immunization
  • Mumps, Measles, Rubella and Varicella (MMRV) Immunization

By Provider

  • Public Provider
  • Private Provider

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

List of key players profiled in the report:

  • Bio-Med Pvt. Limited
  • Changchun BCHT Biotechnology Co. Ltd.
  • Emcure Pharmaceuticals Limited
  • GlaxoSmithKline plc
  • Green Cross Holdings (GC Pharma)
  • Merck & Co. Inc.
  • Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation)
  • Novo Medi Sciences Pvt. Ltd.
  • Sanofi
  • Takeda Pharmaceutical Company Limited

LIST OF OTHER PLAYERS IN THE VALUE CHAIN :

(These players are not profiled in the report. The same will be included on request)

  • VHB Life Sciences
  • Wockhardt Ltd.

Table of Contents

Chapter 1: Introduction

  • 1.1. Report Description
  • 1.2. Key Benefits For Stakeholders
  • 1.3. Key Market Segments
    • 1.3.1. List of Key Players Profiled In The Report
  • 1.4. Research Methodology
    • 1.4.1. Secondary Research
    • 1.4.2. Primary Research
    • 1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

  • 2.1. Key Findings of The Study
  • 2.2. Cxo Perspective

Chapter 3: Market Overview

  • 3.1. Market Definition And Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
  • 3.3. Porter'S Five Forces Analysis
    • 3.3.1. Bargaining Power of Buyers
    • 3.3.2. Bargaining Power of Suppliers
    • 3.3.3. Thereat of New Entrants
    • 3.3.4. Threat of Substitutes
    • 3.3.5. Intensity of Competitive Rivalry
  • 3.4. Top Player Positioning, 2018
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. Surge In Immunization Programs Across The Globe
      • 3.5.1.2. Rise In Awareness Regarding Use of Varicella Live Vaccines
      • 3.5.1.3. Increase In Adoption of Varicella Live Vaccines
    • 3.5.2. Restraint
      • 3.5.2.1. High Monetary Inputs Associated With The Production
    • 3.5.3. Opportunity
      • 3.5.3.1. High Growth Potential In Emerging Economies
    • 3.5.4. Impact Analysis

Chapter 4: Varicella Live Vaccine Market, By Product

  • 4.1. Overview
    • 4.1.1. Market Size And Forecast
  • 4.2. Monovalent Varicella Vaccine
    • 4.2.1. Key Market Trends And Growth Opportunities
    • 4.2.2. Market Size And Forecast, By Region
    • 4.2.3. Market Analysis, By Country
  • 4.3. Combination Varicella Vaccine
    • 4.3.1. Key Market Trends And Growth Opportunities
    • 4.3.2. Market Size And Forecast, By Region
    • 4.3.3. Market Analysis, By Country

Chapter 5: Varicella Live Vaccine Market, By Application

  • 5.1. Overview
    • 5.1.1. Market Size And Forecast
  • 5.2. Chickenpox Immunization
    • 5.2.1. Market Size And Forecast, By Region
    • 5.2.2. Market Analysis, By Country
  • 5.3. Herpes Zoster Immunization
    • 5.3.1. Market Size And Forecast, By Region
    • 5.3.2. Market Analysis, By Country
  • 5.4. Mumps, Measles, Rubella & Varicella (Mmrv) Immunization
    • 5.4.1. Market Size And Forecast, By Region
    • 5.4.2. Market Analysis, By Country

Chapter 6: Varicella Vaccine Market, By Provider

  • 6.1. Overview
    • 6.1.1. Market Size And Forecast
  • 6.2. Public
    • 6.2.1. Market Size And Forecast, By Region
    • 6.2.2. Market Analysis, By Country
  • 6.3. Private
    • 6.3.1. Market Size And Forecast, By Region
    • 6.3.2. Market Analysis, By Country

Chapter 7: Varicella Live Vaccine Market, By Region

  • 7.1. Overview
    • 7.1.1. Market Size And Forecast
  • 7.2. North America
    • 7.2.1. Key Market Trends And Opportunities
    • 7.2.2. Market Analysis By Country
      • 7.2.2.1. U.S.
      • 7.2.2.1.1. U.S. Market Size And Forecast, By Product
      • 7.2.2.1.2. U.S. Market Size And Forecast, By Application
      • 7.2.2.1.3. U.S. Market Size And Forecast, By Provider
      • 7.2.2.2. Canada
      • 7.2.2.2.1. Canada Market Size And Forecast, By Product
      • 7.2.2.2.2. Canada Market Size And Forecast, By Application
      • 7.2.2.2.3. Canada Market Size And Forecast, By Provider
      • 7.2.2.3. Mexico
      • 7.2.2.3.1. Mexico Market Size And Forecast, By Product
      • 7.2.2.3.2. Mexico Market Size And Forecast, By Application
      • 7.2.2.3.3. Mexico Market Size And Forecast, By Provider
    • 7.2.3. North America Market Size And Forecast, By Product
    • 7.2.4. North America Market Size And Forecast, By Application
    • 7.2.5. North America Market Size And Forecast, By Provider
  • 7.3. Europe
    • 7.3.1. Key Market Trends And Opportunities
    • 7.3.2. Market Analysis By Country
      • 7.3.2.1. Germany
      • 7.3.2.1.1. Germany Market Size And Forecast, By Product
      • 7.3.2.1.2. Germany Market Size And Forecast, By Application
      • 7.3.2.1.3. Germany Market Size And Forecast, By Provider
      • 7.3.2.2. France
      • 7.3.2.2.1. France Market Size And Forecast, By Product
      • 7.3.2.2.2. France Market Size And Forecast, By Application
      • 7.3.2.2.3. France Market Size And Forecast, By Provider
      • 7.3.2.3. Uk
      • 7.3.2.3.1. Uk Market Size And Forecast, By Product
      • 7.3.2.3.2. Uk Market Size And Forecast, By Application
      • 7.3.2.3.3. Uk Market Size And Forecast, By Provider
      • 7.3.2.4. Italy
      • 7.3.2.4.1. Italy Market Size And Forecast, By Product
      • 7.3.2.4.2. Italy Market Size And Forecast, By Application
      • 7.3.2.4.3. Italy Market Size And Forecast, By Provider
      • 7.3.2.5. Spain
      • 7.3.2.5.1. Spain Market Size And Forecast, By Product
      • 7.3.2.5.2. Spain Market Size And Forecast, By Application
      • 7.3.2.5.3. Spain Market Size And Forecast, By Provider
      • 7.3.2.6. Rest of Europe
      • 7.3.2.6.1. Rest of Europe Market Size And Forecast, By Product
      • 7.3.2.6.2. Rest of Europe Market Size And Forecast, By Application
      • 7.3.2.6.3. Rest of Europe Market Size And Forecast, By Provider
    • 7.3.3. Europe Market Size And Forecast, By Product
    • 7.3.4. Europe Market Size And Forecast, By Application
    • 7.3.5. Europe Market Size And Forecast, By Provider
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends And Opportunities
    • 7.4.2. Market Analysis By Country
      • 7.4.2.1. Japan
      • 7.4.2.1.1. Japan Market Size And Forecast, By Product
      • 7.4.2.1.2. Japan Market Size And Forecast, By Application
      • 7.4.2.1.3. Japan Market Size And Forecast, By Provider
      • 7.4.2.2. China
      • 7.4.2.2.1. China Market Size And Forecast, By Product
      • 7.4.2.2.2. China Market Size And Forecast, By Application
      • 7.4.2.2.3. China Market Size And Forecast, By Provider
      • 7.4.2.3. Australia
      • 7.4.2.3.1. Australia Market Size And Forecast, By Product
      • 7.4.2.3.2. Australia Market Size And Forecast, By Application
      • 7.4.2.3.3. Australia Market Size And Forecast, By Provider
      • 7.4.2.4. India
      • 7.4.2.4.1. India Market Size And Forecast, By Product
      • 7.4.2.4.2. India Market Size And Forecast, By Application
      • 7.4.2.4.3. India Market Size And Forecast, By Provider
      • 7.4.2.5. South Korea
      • 7.4.2.5.1. South Korea Market Size And Forecast, By Product
      • 7.4.2.5.2. South Korea Market Size And Forecast, By Application
      • 7.4.2.5.3. South Korea Market Size And Forecast, By Provider
      • 7.4.2.6. Rest of Asia-Pacific
      • 7.4.2.6.1. Rest of Asia-Pacific Market Size And Forecast, By Product
      • 7.4.2.6.2. Rest of Asia-Pacific Market Size And Forecast, By Application
      • 7.4.2.6.3. Rest of Asia-Pacific Market Size And Forecast, By Provider
    • 7.4.3. Asia-Pacific Market Size And Forecast, By Product
    • 7.4.4. Asia-Pacific Market Size And Forecast, By Application
    • 7.4.5. Asia-Pacific Market Size And Forecast, By Provider
  • 7.5. Lamea
    • 7.5.1. Key Market Trends And Opportunities
    • 7.5.2. Market Analysis By Country
      • 7.5.2.1. Brazil
      • 7.5.2.1.1. Brazil Market Size And Forecast, By Product
      • 7.5.2.1.2. Brazil Market Size And Forecast, By Application
      • 7.5.2.1.3. Brazil Market Size And Forecast, By Provider
      • 7.5.2.2. Saudi Arabia
      • 7.5.2.2.1. Saudi Arabia Market Size And Forecast, By Product
      • 7.5.2.2.2. Saudi Arabia Market Size And Forecast, By Application
      • 7.5.2.2.3. Saudi Arabia Market Size And Forecast, By Provider
      • 7.5.2.3. South Africa
      • 7.5.2.3.1. South Africa Market Size And Forecast, By Product
      • 7.5.2.3.2. South Africa Market Size And Forecast, By Application
      • 7.5.2.3.3. South Africa Market Size And Forecast, By Provider
      • 7.5.2.4. Rest of Lamea
      • 7.5.2.4.1. Rest of Lamea Market Size And Forecast, By Product
      • 7.5.2.4.2. Rest of Lamea Market Size And Forecast, By Application
      • 7.5.2.4.3. Rest of Lamea Market Size And Forecast, By Provider
    • 7.5.3. Lamea Market Size And Forecast, By Product
    • 7.5.4. Lamea Market Size And Forecast, By Application
    • 7.5.5. Lamea Market Size And Forecast, By Provider

Chapter 8: Company Profiles

  • 8.1. Bio-Med Pvt. Limited
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Product Portfolio
    • 8.1.4. Key Strategic Moves And Developments
  • 8.2. Changchun Bcht Biotechnology Co. Ltd.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Product Portfolio
  • 8.3. Emcure Pharmaceuticals Limited (Zuventus Healthcare Ltd.)
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Product Portfolio
  • 8.4. Glaxosmithkline Plc
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Operating Business Segments
    • 8.4.4. Product Portfolio
    • 8.4.5. Business Performance
  • 8.5. Green Cross Holdings (Gc Pharma)
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Product Portfolio
    • 8.5.4. Business Performance
  • 8.6. Merck & Co. Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Operating Business Segments
    • 8.6.4. Product Portfolio
    • 8.6.5. Business Performance
    • 8.6.6. Key Strategic Moves And Developments
  • 8.7. Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation)
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Operating Business Segments
    • 8.7.4. Product Portfolio
    • 8.7.5. Business Performance
    • 8.7.6. Key Strategic Moves And Developments
  • 8.8. Novo Medi Sciences Pvt. Ltd.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Product Portfolio
  • 8.9. Sanofi
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Operating Business Segments
    • 8.9.4. Product Portfolio
    • 8.9.5. Business Performance
  • 8.10. Takeda Pharmaceutical Company Limited
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Operating Business Segments
    • 8.10.4. Product Portfolio
    • 8.10.5. Business Performance

List of Tables

  • Table 01. Global Varicella Live Vaccine Market, By Products, 2018-2026 ($Million)
  • Table 02. Varicella Live Vaccine Market For Monovalent Varicella Vaccine, By Region, 2018-2026 ($Million)
  • Table 03. Varicella Live Vaccine Market For Combination Varicella Vaccine, By Region, 2018-2026 ($Million)
  • Table 04. Global Varicella Live Vaccine Market, By Application, 2018-2026 ($Million)
  • Table 05. Varicella Live Vaccine Market For Chickenpox Immunization, By Region, 2018-2026 ($Million)
  • Table 06. Varicella Live Vaccine Market For Herpes Zoster, By Region, 2018-2026 ($Million)
  • Table 07. Varicella Live Vaccine Market For Mmrv Immunization, By Region, 2018-2026 ($Million)
  • Table 08. Global Varicella Live Vaccine Market, By Provider, 2018-2026 ($Million)
  • Table 09. Varicella Live Vaccine Market For Public Provider, By Region, 2018-2026 ($Million)
  • Table 10. Varicella Live Vaccine Market For Private Provider, By Region, 2018-2026 ($Million)
  • Table 11. Varicella Live Vaccine Market, By Region, 2018-2026 ($Million)
  • Table 12. North America Varicella Live Vaccine Market Revenue, By Country 2019-2026 ($Million)
  • Table 13. U.S. Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 14. U.S. Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 15. U.S. Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 16. Canada Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 17. Canada Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 18. Canada Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 19. Mexico Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 20. Mexico Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 21. Mexico Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 22. North America Varicella Live Vaccine Market Revenue, By Product 2019-2026($Million)
  • Table 23. North America Varicella Live Vaccine Market Revenue, By Application 2019-2026($Million)
  • Table 24. North America Varicella Live Vaccine Market Revenue, By Provider 2019-2026($Million)
  • Table 25. Europe Varicella Live Vaccine Market Revenue, By Country 2019-2026 ($Million)
  • Table 26. Germany Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 27. Germany Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 28. Germany Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 29. France Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 30. France Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 31. France Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 32. Uk Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 33. Uk Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 34. Uk Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 35. Italy Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 36. Italy Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 37. Italy Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 38. Spain Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 39. Spain Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 40. Spain Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 41. Rest of Europe Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 42. Rest of Europe Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 43. Rest of Europe Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 44. Europe Varicella Live Vaccine Market Revenue, By Product 2019-2026($Million)
  • Table 45. Europe Varicella Live Vaccine Market Revenue, By Application 2019-2026($Million)
  • Table 46. Europe Varicella Live Vaccine Market Revenue, By Provider 2019-2026($Million)
  • Table 47. Asia-Pacific Varicella Live Vaccine Market Revenue, By Country 2019-2026 ($Million)
  • Table 48. Japan Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 49. Japan Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 50. Japan Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 51. China Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 52. China Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 53. China Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 54. Australia Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 55. Australia Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 56. Australia Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 57. India Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 58. India Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 59. India Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 60. South Korea Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 61. South Korea Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 62. South Korea Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 63. Rest of Asia-Pacific Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 64. Rest of Asia-Pacific Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 65. Rest of Asia-Pacific Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 66. Asia-Pacific Varicella Live Vaccine Market Revenue, By Product 2019-2026($Million)
  • Table 67. Asia-Pacific Varicella Live Vaccine Market Revenue, By Application 2019-2026($Million)
  • Table 68. Asia-Pacific Varicella Live Vaccine Market Revenue, By Provider 2019-2026($Million)
  • Table 69. Lamea Varicella Live Vaccine Market Revenue, By Country 2019-2026 ($Million)
  • Table 70. Brazil Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 71. Brazil Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 72. Brazil Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 73. Saudi Arabia Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 74. Saudi Arabia Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 75. Saudi Arabia Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 76. South Africa Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 77. South Africa Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 78. South Africa Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 79. Rest of Lamea Varicella Live Vaccine Market Revenue, By Product 2019-2026 ($Million)
  • Table 80. Rest of Lamea Varicella Live Vaccine Market Revenue, By Application 2019-2026 ($Million)
  • Table 81. Rest of Lamea Varicella Live Vaccine Market Revenue, By Provider 2019-2026 ($Million)
  • Table 82. Lamea Varicella Live Vaccine Market Revenue, By Product 2019-2026($Million)
  • Table 83. Lamea Varicella Live Vaccine Market Revenue, By Application 2019-2026($Million)
  • Table 84. Lamea Varicella Live Vaccine Market Revenue, By Provider 2019-2026($Million)
  • Table 85. Bio-Med: Company Snapshot
  • Table 86. Bio-Med: Product Portfolio
  • Table 87. Changchun Baike: Company Snapshot
  • Table 88. Changchun Baike: Product Portfolio
  • Table 89. Emcure : Company Snapshot
  • Table 90. Emcure: Product Portfolio
  • Table 91. Gsk: Company Snapshot
  • Table 92. Gsk: Operating Segments
  • Table 93. Gsk: Product Portfolio
  • Table 94. Gc: Company Snapshot
  • Table 95. Gc: Product Portfolio
  • Table 96. Merck: Company Snapshot
  • Table 97. Merck: Operating Segments
  • Table 98. Merck: Product Portfolio
  • Table 99. Mchc Group: Company Snapshot
  • Table 100. Mchc Group: Operating Segments
  • Table 101. Mchc Group: Product Portfolio
  • Table 102. Novo: Company Snapshot
  • Table 103. Novo: Product Portfolio
  • Table 104. Sanofi: Company Snapshot
  • Table 105. Sanofi: Operating Segments
  • Table 106. Sanofi: Product Portfolio
  • Table 107. Takeda: Company Snapshot
  • Table 108. Takeda: Operating Segments
  • Table 109. Takeda: Product Portfolio

List of Figures

  • Figure 01. Global Varicella Live Vaccine Market Segmentation
  • Figure 02. Top Investment Pockets, 2018
  • Figure 03. Moderate Bargaining Power of Buyers
  • Figure 04. Moderate Bargaining Power of Suppliers
  • Figure 05. Low Threat of New Entrants
  • Figure 07. Moderate Competitive Rivalry
  • Figure 08. Top Player Positioning, 2018
  • Figure 09. Impact Analysis, Varicella Live Vaccine Market
  • Figure 10. Comparative Analysis of Varicella Live Vaccine Market For Monovaent Vaccine, By Country, 2018 & 2026 ($Million)
  • Figure 11. Comparative Analysis of Varicella Live Vaccine Market For Combination Varicella Vaccine, By Country, 2018 & 2026 ($Million)
  • Figure 12. Comparative Analysis of Varicella Live Vaccine Market For Chickenpox Immunization, By Country, 2018 & 2026 ($Million)
  • Figure 13. Comparative Analysis of Varicella Live Vaccine Market For Herpes Zoster, By Country, 2018 & 2026 ($Million)
  • Figure 14. Comparative Analysis of Varicella Live Vaccine Market For Mmrv Immunization, By Country, 2018 & 2026 ($Million)
  • Figure 15. Comparative Analysis of Varicella Live Vaccine Market For Public Provider, By Country, 2018 & 2026 ($Million)
  • Figure 16. Comparative Analysis of Varicella Live Vaccine Market For Private Provider, By Country, 2018 & 2026 ($Million)
  • Figure 17. Gsk: Net Sales, 2016-2018 ($Million)
  • Figure 18. Gsk: Revenue Share By Segment, 2018 (%)
  • Figure 19. Gsk: Revenue Share By Region, 2018 (%)
  • Figure 20. Gc: Net Sales, 2015-2017 ($Million)
  • Figure 21. Gc: Revenue Share By Region, 2018 (%)
  • Figure 22. Merck: Net Sales, 2016-2018 ($Million)
  • Figure 23. Merck: Revenue Share By Segment, 2018 (%)
  • Figure 24. Merck: Revenue Share By Region, 2018 (%)
  • Figure 25. Mchc Group: Net Sales, 2016-2018 ($Million)
  • Figure 26. Mchc Group: Revenue Share By Segment, 2018 (%)
  • Figure 27. Sanofi: Net Sales, 2016-2018 ($Million)
  • Figure 28. Sanofi: Revenue Share By Segment, 2018 (%)
  • Figure 29. Sanofi: Revenue Share By Region, 2018 (%)
  • Figure 30. Takeda: Net Sales, 2016-2018 ($Million)
  • Figure 31. Takeda: Revenue Share By Segment, 2018 (%)
  • Figure 32. Takeda: Revenue Share By Region, 2018 (%)
Back to Top